Drug, produced from pigs offers hope to vascular dementia patients
Called cerebrolysin, drug aids in memory and overall mood of test subjects
Those who suffer from the debilitating condition known as dementia may now benefit from a "promising" new treatment made from pigs' brains, researchers say. Called cerebrolysin, the drug improves concentration, memory processing and mood in patients who suffer from a variant of the condition known as vascular dementia.
The new drug is licensed in some countries for dementia, stroke and traumatic brain injury -- not yet either in the U.S. or U.K.
"Our review suggests that Cerebrolysin can help improve cognitive and global function in patients with mild to moderate severity vascular dementia," Researcher Li He of the Department of Neurology at Sichuan University in Sichuan, China says.
The drug is produced from pig brain proteins which have produced some positive results from small vascular dementia trials. Larger trials are currently underway.
The drug is not easy to administer. In order for effectiveness, regular intravenous infusions are necessary. The review analyzed the most up-to-date evidence from six trials involving 597 people.
All test subjects were given Cerebrolysin intravenously in different daily concentrations for different treatment periods, from a few weeks to three years, depending on the trial.
Cerebrolysin had been found to have significantly improved brain function based on testing recall, arithmetic or other cognitive abilities.
It also had a small positive effect on patients" overall clinical state and mood. Long-term treatment may have greater benefits, although most of the trials were short.
Vascular dementia is a common form of dementia. It occurs following damage to the network of blood vessels supplying the brain.
While some symptoms are similar to Alzheimer's disease and stroke, people with vascular dementia often experience difficulty thinking quickly, concentrating and communicating, as well as seizures and severe confusion.
"The results are promising but due to low numbers of trials, inconsistencies between trials, risk of bias in the way some of the trials were conducted and lack of long-term follow-up, we cannot yet recommend Cerebrolysin as a routine treatment for vascular dementia," Dr. He said.
In addition, no serious side effects were reported due to taking the drug.
"This indicates to U.S. that Cerebrolysin is safe and well tolerated by patients with vascular dementia," He said. But the fact that it has to be given in regular intravenous infusions means it could be impractical for use on a large scale."
"This review found that Cerebrolysin does appear to have some cognitive benefits for people with vascular dementia, although it is not clear how these might translate into day-to-day improvements in people's lives," Dr. Eric Karran, director of research at Alzheimer's Research U.K. says.
"It is positive to see potential new treatments tested in people, but larger clinical trials are needed before we could know whether Cerebrolysin could be a feasible treatment option for people with the condition.
"Research into new treatments is absolutely vital, but without continued investment, promising findings cannot be taken forward. We must ensure that research into dementia remains a national priority."
© 2014 - Distributed by THE NEWS CONSORTIUM
Pope Francis Prayer Intentions for March 2014
Respect for Women: That all cultures may respect the rights and dignity of women.
Vocations: That many young people may accept the Lordís invitation to consecrate their lives to proclaiming the Gospel.
Rate This Article
Leave a Comment
More Health News
- New blood test diagnoses Alzheimer's three years before onset of disease
- Malaria spreads to higher altitudes due to global warming
- Malaria cases spread to higher elevations
- Alzheimer's to join cancer, heart disease as one of America's top fatal conditions
- Birthing centers not provided for under health care reform
- Lots of proteins can BE BAD FOR YOU! 'As bad for health as smoking,' new study finds
- OUTBREAK: 53 people in 10 states stricken with measles
- Popular overdose drug rises in cost, to keep up with demand
- ANCIENT SCOURGE: leprosy, still very much alive in the world today, goes back 10 million years
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?